首页AutophagyRaf
Raf
T0093 Sorafenib tosylate Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
T0093L Sorafenib Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-4/B-Raf).
T10157 Regorafénib N-oxyde (M2) Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2/46, 1.5, 22, 7,
T10567 BMS-214662 BMS-214662 is an effective and selective inhibitor of farnesyl transferase with potent antitumor activity (IC50: 1.35 nM).
T10599 BRAF inhibitor BRAF inhibitor is an inhibitor of B-Raf extracted from patent WO/2011103196 A1 (Compound P-0850).
T11224 ERK-IN-1 ERK-IN-1  is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly relate
T11898 LXH254 LXH254 is a potent C-Raf and B-Raf inhibitor.
T12556 PROTAC B-Raf degrader 1 PROTAC B-Raf degrader 1 is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf,PROTAC B-Raf degrader 1 With anti-cancer activity.
T12978 SOS1-IN-1 SOS1-IN-1 is an inhibitor of SOS1.
T13406L Zabofloxacin hydrochloride Zabofloxacin hydrochloride is a potent and seletive bacterial type II and IV topoisomerases inhibitor, has excellent activity against gram-positive pathogens including Steptococcus
T15804 LY2452473 LY2452473 is an orally bioavailable and selective androgen receptor modulator.
T1792 Regorafenib Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
T1792L Regorafenib monohydrate Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, R
T1845 B-Raf IN 1 B-Raf IN 1 is a B-Raf (IC50: 24 nM) and c-Raf (IC50: 25 nM) inhibitor.
T1851 ZM 336372 ZM 336372 is a potent and selective c-Raf inhibitor.
T1876 Kobe0065 Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Ra
T1886 TAK632 TAK-632 is a potent pan-Raf inhibitor.
T1892 Kobe2602 Kobe 2602 is an inhibitor of Ras that exhibits anticancer chemotherapeutic activities.
T1903 Dabrafenib Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase (IC50s: 0.7/5 nM for B-Raf (V600E)/C-Raf).
T1931 6H05 6H05 is a selective, allosteric inhibitor of oncogenic mutant K-Ras(G12C).
T1953 L779450 L-779450, an effective, ATP-competitive Raf kinase inhibitor (IC50: 10 nM) , displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively.
T2074 B-Raf inhibitor 1 B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor.
T2293 SGX523 SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
T2295 SB590885 SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay). The selectivity of SB590885 for B-Raf is 11-fold greater over c-Raf, no acts to other human kinases.
T2327 Pelitinib Pelitinib (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
T2382 Vemurafenib Vemurafenib (PLX4032) is a novel and potent B-Raf (V600E) inhibitor (IC50: 31 nM).
T2473 PLX4720 PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
T2624 OSI 930 OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesi
T3579 PLX8394 PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutate
T3641 BAW2881 BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammati
T3711 RAF709 RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
T3725 K-Ras(G12C) Inhibitor 6 K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant that causes 100% modification of the protein when used at 10 μM for 24 hours in vitro.
T4133 CCT196969 CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
T4167 B-Raf inhibitor 1 dihydrochloride B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor.
T4194 CID25014542 CID-25014542 is novel inhibitor of Raf kinases.
T4301 AD80 AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
T5172 AZ304 AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).
T5418 BAY-293 BAY-293 is a potent, cell-active SOS1 inhibitor that disrupts the KRAS-SOS1 interaction (IC50: 21 nM).
T5634 Belvarafenib Belvarafenib is a potent and pan RAF inhibitor with antineoplastic activity. The IC50 values of Belvarafenib are 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
T6003 GSK1904529A GSK1904529A is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
T6052 GW 441756 GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
T6169 Indirubin Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 uM and 0.6 uM.
T6302 Lonafarnib Lonafarnib is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B, and N-ras (IC50: 1.9/5.2/2.8 nM).
T6320 GDC0879 GDC-0879 is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well.
T6348 NVP-BHG712 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0
T6487 Encorafenib LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
T6525 GW5074 GW5074(IC50=9 nM) is an effective and specific c-Raf inhibitor. It has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.
T6555 K-Ras(G12C) inhibitor 12 K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C).
T6556 K-Ras(G12C) inhibitor 9 K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).
T6882 LY3009120 LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
T6895 MLN2480 MLN2480 is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials.
T6948 Pluripotin Pluripotin (SC1), which keep embryonic stem cell (ESC) self-renewal, is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP.
T6949 PLX7904 PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. It is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does
T6971 RO5126766 RO5126766 (CH5126766) is a dual RAF/MEK inhibitor with IC50 of 8.2 nM, 19 nM, 56 nM, and 160 nM for BRAF V600E, BRAF, CRAF, and MEK1, respectively. Phase 1.
T7414 ARS-853 ARS-853 is an inhibitor of K-RASG12C(IC50 : 2.5 μM), a mutant form of K-RAS that accumulates in the active GTP-bound state in certain cancer cells
T8402 Regorafenib Hydrochloride Regorafenib Hydrochloride is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
T8474 Dabrafenib Mesylate Dabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
T8654 Plx-4032 PLX-4032 is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
T8721 I-37 I-37 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
T8721L I-37 free base( 2359690-13-2(free base)) I-37 free base is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
T8745 Compound 23 Compound 23 selectively induces degradation of BRAF-V600E but not wildtype BRAF.
T8746L I-49 free base I-49 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
T8823 Locostatin Locostatin is a potent and cell permeable inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.
TN2114 Pseudoginsenoside Rh2 Pseudoginsenoside Rh2 has cytotoxicity, it induces mitochondrial apoptosis in A549 cells and is responsible for excessive activation of the Ras/Raf/ERK/p53 pathway. (20Z) -Pseudogi
TN4166 Griffipavixanthone Griffipavixanthone inhibits the growth of human Non-small-cell lung cancer H520 cells in dose- and time-dependent manners, it induces cell apoptosis through mitochondrial apoptotic
TQ0048 BI-882370 BI-882370 is a specific RAF kinase inhibitor. BI-882370 inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases (IC50s: 0.4, 0.8 and 0.6 nM). BI-882370 also inhibits
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。